Last reviewed · How we verify

T.Prazosin — Competitive Intelligence Brief

T.Prazosin (T.Prazosin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

T.Prazosin (T.Prazosin) — Haffkine Bio-Pharmaceutical Corporation Ltd.. T.Prazosin is an alpha-1 adrenergic receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
T.Prazosin TARGET T.Prazosin Haffkine Bio-Pharmaceutical Corporation Ltd. phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor
Metoprolol succinate + doxazosin Metoprolol succinate + doxazosin University of Colorado, Denver marketed Beta-blocker + Alpha-1 adrenergic antagonist combination Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor
Bolus Phenylephrine/Ephedrine Treatment Bolus Phenylephrine/Ephedrine Treatment IWK Health Centre marketed Sympathomimetic amines / Vasopressors Alpha-1 adrenergic receptor (phenylephrine); Alpha and beta adrenergic receptors (ephedrine)
Norepinephrine (10 µg boluses) Norepinephrine (10 µg boluses) Hopital Charles Nicolle marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Phenylephrine bolus 50 micrograms Phenylephrine bolus 50 micrograms Rawalpindi Medical College marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor
Brompheniramine + pseudoephedrine Brompheniramine + pseudoephedrine Ache Laboratorios Farmaceuticos S.A. marketed Antihistamine + decongestant combination H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)
CarVeDilol-SR (Slow Release) CarVeDilol-SR (Slow Release) Seoul National University Bundang Hospital marketed Beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

  1. Brian J Lipworth · 1 drug in this class
  2. CHU de Quebec-Universite Laval · 1 drug in this class
  3. Eli Lilly and Company · 1 drug in this class
  4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
  5. Hospital Authority, Hong Kong · 1 drug in this class
  6. Japan Heart Foundation · 1 drug in this class
  7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
  8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
  9. Sanofi · 1 drug in this class
  10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). T.Prazosin — Competitive Intelligence Brief. https://druglandscape.com/ci/t-prazosin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: